Bernie Haffey Named Chief Commercial Officer at SightLife Surgical

May 12, 2017: By Joan McKenna

SightLifeSurgicalPaul Bernard “Bernie” Haffey has joined SightLife Surgical as its first chief commercial officer.

SightLife Surgical, founded in 2016, is a Seattle-based for-profit subsidiary of SightLife that provides comprehensive services to support ophthalmic surgeons, from corneal tissue and devices to reimbursement consulting and political advocacy.

“Given our ambitions to accelerate discoveries that will benefit the cornea world, from surgeons to patients, Bernie’s background launching emerging medical technology companies, as well as his proven history of creating shareholder value, will help us reach our goal to eliminate corneal blindness by 2040,” said Monty Montoya, SightLife Surgical president and CEO.

Most recently, Haffey served as president and CEO of Nexis Vision, Inc., and president and CEO of NDO Surgical, Inc. He also served as executive vice president and chief commercial officer at Summit Technology, Inc., and as executive vice president and chief commercial officer at IntraLase Corp. In addition to his role at SightLife, Bernie serves as president of 2020 Management Consulting, Inc.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022